Seller record · Telehealth service

MyStart Health

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. The disclosures refer only to licensed U.S. pharmacies compounding under Section 503A, and the medication safety page refers the patient to the pharmacy listed on the prescription label. 1 more criterion also fails; see the table below.

At a glance

MyStart HealthTelehealth service

6/8criteria passed

Price: Program from $299 a month before discounts
Sells: compounded GLP-1 medication, compounded tirzepatide
FDA letters: 1 on file

Visit MyStart Health See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform selling an all-inclusive compounded GLP-1 weight loss membership, with physician visits, medication, lab work and shipping in one monthly price, through an outside network of licensed providers. Care starts with an online health questionnaire before the order, no pharmacy is named, and an FDA warning letter names its operating company.

Operating entity MyStart Health LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	MyStart Health's website; MyStart Health's disclosures page
S2	Prescription gating	PASS	MyStart Health's FAQ; MyStart Health's website
S3	Pharmacy identification	FAIL	MyStart Health's disclosures page; MyStart Health's medication safety information page; MyStart Health's website
S4	Compounding disclosure	PASS	MyStart Health's website; MyStart Health's disclosures page
S5	Analytical documentation	FAIL	MyStart Health's FAQ; MyStart Health's disclosures page
S6	Business address	PASS	MyStart Health's website; MyStart Health's terms and conditions; MyStart Health's privacy policy
S7	Price disclosure	PASS	MyStart Health's website; MyStart Health's refund policy
S8	Enforcement status	PASS	FDA's website; FDA warning letter 714755

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSMedical evaluations are provided by licensed providers in an affiliated telehealth network who alone decide whether to prescribe, a telehealth consultation with a licensed provider is required after checkout, and the home page names the chief medical advisor.Source: MyStart Health's website; MyStart Health's disclosures page.

S2PASSThe answers list an online questionnaire about health history and weight loss goals as the first step, then the order, then the medical intake and a doctor's prescription, and say payment follows the pre-qualification questionnaire and is refunded in full if a doctor finds the patient ineligible. The disclosure on every page says screening answers can exclude a patient before evaluation.Source: MyStart Health's FAQ; MyStart Health's website.

S3FAILNo filling pharmacy is named. The disclosures refer only to licensed U.S. pharmacies compounding under Section 503A, and the medication safety page refers the patient to the pharmacy listed on the prescription label.Source: MyStart Health's disclosures page; MyStart Health's medication safety information page; MyStart Health's website.

S4PASSThe compounded medication notice on every page and the disclosure policy state that the compounded GLP-1 medications are not approved by the FDA and have not been evaluated for safety, efficacy or manufacturing consistency.Source: MyStart Health's website; MyStart Health's disclosures page.

S5FAILNo certificate of analysis or lot document is published. The answers say the medication passes third-party quality and sterility testing, with no report behind the claim.Source: MyStart Health's FAQ; MyStart Health's disclosures page.

S6PASSMyStart Health LLC at 254 Chapman Rd., STE 209 #17801, Newark, DE 19702, printed in the footer of every page and in the terms, the privacy policy, the refund policy and the disclosures.Source: MyStart Health's website; MyStart Health's terms and conditions; MyStart Health's privacy policy.

S7PASSThe program costs from $299 a month, excluding discounts, covering physician visits, a 4-week or 12-week supply of compounded medication, any lab work and shipping, and the answers say the price does not rise with the dose. A banner offers $150 off and 25% off for life.Source: MyStart Health's website; MyStart Health's refund policy.

S8PASSFDA warning letter 714755, September 2025, names MyStart Health LLC and its chief executive at the Newark, Delaware address the site prints, one digit apart in the suite number, and it reviewed the seller's own website. It alleges that claims such as Generic Ozempic and generics with the same active ingredients and results present compounded semaglutide as the same as an FDA-approved product when it is not. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 714755.

Products shown on the seller's own pages at the recorded date: compounded GLP-1 medication, compounded tirzepatide.

Other sellers of the same products

Who sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 714755, issued September 2025, to Matthew Stern, CEO MyStart Health LLC.Claims on MyStart Health's website such as Generic Ozempic and generics with the same active ingredients and results imply that compounded semaglutide is the same as an FDA-approved product when it is not.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit MyStart Health

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.